Prevalence and Detection Practices

Panelists discuss how FGFR2b has emerged as a clinically relevant biomarker in gastric and gastroesophageal junction cancers. FGFR2b represents a receptor isoform whose overexpression or amplification correlates with aggressive disease biology and distinct therapeutic opportunities. The panel explains that its identification expands the spectrum of targetable alterations beyond previously established markers, highlighting the ongoing refinement of molecular taxonomy in gastric cancer.

Detection practices for FGFR2b alterations currently rely on validated immunohistochemistry assays and complementary genomic methods. These tools enable precise identification of protein overexpression or gene amplification, allowing clinicians to stratify patients for investigational or approved therapies targeting the FGFR2b pathway. The discussion emphasizes that test selection should balance accuracy, turnaround time, and tissue preservation, as gastric tumors are often heterogeneous and sample quality can be a limiting factor.

Panelists also outline the principal categories of investigational FGFR2b-targeted treatments, including selective inhibitors, pan-FGFR inhibitors, monoclonal antibodies, and antibody–drug conjugates. Each approach employs a distinct mechanism to disrupt FGFR2b signaling or deliver cytotoxic payloads, offering multiple potential therapeutic avenues.
In summary, panelists note that FGFR2b detection is refining patient stratification and expanding targeted therapy options within the evolving landscape of gastric cancer management.